Avitop GmbH

  • Land: Deutschland

Nachricht vom 12.10.2015 | 08:30

Avitop Obtains US and EU Authorization for Nutraceutical CorriXTM and Announces Product Launch


DGAP-News: Avitop GmbH / Key word(s): Product Launch/Market launch

2015-10-12 / 08:30


Press release
Meant only for specialists.

Avitop Obtains US and EU Authorization for Nutraceutical CorriXTM and Announces Product Launch

Berlin, Germany, October 12, 2015 - Avitop GmbH, a Berlin-based biotech company developing next generation nutraceuticals, announced today that the Company has obtained European Novel Food authorization from the European Commission for CorriXTM, a nutraceutical containing the Company's proprietary strain Bacteroides xylanisolvens DSM 23964 under Regulation (EC) No 258/97 of the European Parliament and of the Council.

Recently, the US Food and Drug Administration (FDA) granted (letter of no objection) B. xylanisolvens DSM 23964 and heat-treated milk products fermented with this strain "Generally Recognized As Safe" (GRAS) status for use in dairy and other food applications (GRAS Notice No. GRN 000457). Based, in part, on GRAS status Avitop then determined that B. xylanisolvens DSM 23964 is appropriate for use as a dietary ingredient in the Company's new line of CorriXTM supplements.

"Achieving GRAS and Novel Food status is a major milestone for Avitop and allows for accelerated product development and commercialization both in the United States and Europe", said Dr. Philippe Ulsemer, Director of Avitop GmbH. "Numerous studies have shown that microorganisms naturally inhabiting our body are crucially involved in our health and well-being. We are fully committed to use our know-how, technologies and ingenuity to develop new probiotic, nutraceutical and food concepts with unmet functionality to provide customers with a new generation of functional food that will help to manage health and well-being from the inside-out."

Potential unique health benefits of Bacteroides xylanisolvens DSM 23964

Avitop invests significant resources in scientific research to investigate the potential health benefit of B. xylanisolvens DSM 23964, a new strain that was primarily characterized in 2012 (Applied and Environment Microbiology, 2012, 78: 528-535).

Avitop recently identified this strain to carry the "Thomsen-Friedenreich antigen" (TF) on its surface. Strains carrying this antigen were reported to be able to induce the development of specific antibodies (IgMs) directed against the TF-antigen in vivo and a higher level of such natural TF-antibodies in humans were reported to benefit the natural function of the immune system. As a consequence, Avitop believes that the regular consumption of a product containing the strain B. xylanisolvens DSM 23964 will support the development of natural TF-antibodies, thereby providing significant health benefit. Avitop is currently running human studies to investigate this assumption.

About Avitop GmbH:

Avitop is a German Biotech Company based in Berlin developing the next generation of nutraceuticals. "CorriXTM", the front running project of Avitop is a heat-treated fermented milk produced with B. xylanisolvens DSM 23964, a proprietary bacterial strain with potential positive effects to the immune system. Parallel to obtaining US and European market authorization, a new industrial-scale production process was established. In a next step, Avitop is building worldwide alliances for marketing and distribution of "CorriXTM".

Contact:

Avitop GmbH
Dr. Philippe Ulsemer, Director
 
Robert-Roessle-Str. 10
13125 Berlin, Germany
 
T: +49 (0) 30 9489 2600
F: +49 (0) 30 9489 2634
E: info@avitop.de
 
Website: www.avitop.de




2015-10-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


401641  2015-10-12 

GBC im Fokus

Virtuelle Konferenz: International Investment Forum am 19.05.2022

Das International Investment Forum (IIF) bietet als rein digitales Live-Event Zugang zu börsennotierten Unternehmen aus den Small- und Midcap-Segmenten aus aller Welt. Speaker am 19. Mai 2022 ab 9:55 sind Vorstände börsennotierter Gesellschaften aus den Sektoren Rohstoffe, Immobilien, Energie, Chiptechnik, Biotechnologie, Crypto und Raumfahrt. Die präsentierenden Vorstände bieten einmalige Einblicke und stehen live für Fragen aller Investorengruppen zur Verfügung.

News im Fokus

Vonovia SE: Die Hälfte der Aktionärinnen und Aktionäre entscheidet sich für Aktiendividende bei Vonovia (News mit Zusatzmaterial)

19. Mai 2022, 14:49

Aktueller Webcast

fashionette AG

Earnings Call Q1 2022

19. Mai 2022

Aktuelle Research-Studie

MOBOTIX AG

Original-Research: MOBOTIX AG (von Montega AG): Halten

20. Mai 2022